List of Excipients in Branded Drug AVANDIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	CELLULOSE, MICROCRYSTALLINE
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	FERRIC OXIDE RED
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	FERRIC OXIDE YELLOW
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	HYPROMELLOSE 2910
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	LACTOSE MONOHYDRATE
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	MAGNESIUM STEARATE
GlaxoSmithKline LLC	AVANDIA	rosiglitazone maleate	0173-0861	POLYETHYLENE GLYCOL 3000

AVANDIA Excipient Strategy and Commercial Opportunities for Rosiglitazone

Last updated: September 24, 2026

Avandia is the branded formulation of rosiglitazone maleate, an oral thiazolidinedione approved by the FDA for type 2 diabetes. Its core tablet technology is mature, low-cost and technically accessible to generic manufacturers. The main commercial opportunities are not based on recreating the branded product. They are based on reliable low-dose content uniformity, improved manufacturability, differentiated fixed-dose combinations, patient-friendly dosage forms and supply-chain economics.

Rosiglitazone has limited branded commercial value because FDA exclusivity and the principal patent barriers have expired, generic products are available, and cardiovascular safety restrictions materially reduced demand. The active pharmaceutical ingredient remains suitable for low-cost solid oral development, but a new product would need a clear clinical, adherence, geographic or manufacturing advantage.

What excipients are used in Avandia tablets?

The Avandia tablet is a conventional immediate-release, film-coated tablet. The formulation uses widely available pharmaceutical excipients rather than specialized delivery technology.

Formulation component	Reported role
Rosiglitazone maleate	Active pharmaceutical ingredient
Lactose monohydrate	Diluent and tablet mass builder
Microcrystalline cellulose	Diluent, dry binder and compression aid
Sodium starch glycolate	Superdisintegrant
Hydroxypropyl methylcellulose	Binder or film-coating polymer
Magnesium stearate	Lubricant
Titanium dioxide and colorants	Film-coating opacity and product identification
Triacetin	Plasticizer in the film coat

The exact quantitative composition varies by strength and manufacturing presentation. The FDA-approved product is supplied in 2 mg, 4 mg and 8 mg tablets, with color coding used to distinguish strengths. FDA labeling identifies the product as rosiglitazone maleate tablets and describes oral administration without a modified-release mechanism (U.S. Food and Drug Administration [FDA], 2010).

Why is the Avandia excipient platform commercially practical?

The formulation relies on an established lactose-cellulose-disintegrant system. This supports:

• Direct compression or a short granulation process.
• Broad supplier availability.
• Low excipient cost.
• Established compendial testing.
• Straightforward scale-up.
• Conventional immediate-release dissolution testing.
• A low regulatory burden relative to modified-release products.

The formulation does not require lipid-based delivery, enteric protection, osmotic technology, nanomilling or a specialized capsule-in-capsule system. That limits formulation differentiation but reduces technical risk for generic development.

What excipient strategy is appropriate for generic rosiglitazone?

A generic manufacturer should prioritize bioequivalent performance, content uniformity and manufacturing robustness over cosmetic replication of every branded excipient.

Direct-compression strategy

A direct-compression formulation can use microcrystalline cellulose, lactose, sodium starch glycolate and magnesium stearate. This approach minimizes processing steps and is economically attractive for a low-volume mature product.

The principal development risks are:

• Poor flow from the low-dose active ingredient.
• Segregation during blending or transfer.
• Compression variability at the 2 mg strength.
• Over-lubrication from excessive magnesium stearate.
• Slow disintegration caused by excessive lubricant or binder.
• Dissolution changes caused by particle-size differences in rosiglitazone maleate.

The 2 mg tablet is the most formulation-sensitive strength because the active represents a small fraction of total tablet weight. Geometric dilution, controlled blending time and validated segregation controls are more important than simply matching the reference product’s excipient list.

Wet-granulation strategy

Wet granulation can improve blend uniformity and flow where the active has poor bulk density or unfavorable particle-size distribution. It may also produce better tablet weight control on high-speed presses.

The trade-offs are higher process cost, additional residual-moisture controls and possible impact on chemical stability. The formulation should establish whether rosiglitazone maleate is stable under the selected granulation and drying conditions before adopting this process.

Excipient selection priorities

Development objective	Preferred excipient approach
Low manufacturing cost	Lactose and microcrystalline cellulose with direct compression
Improved flow	Granulated lactose, silicified microcrystalline cellulose or controlled granulation
Better low-dose uniformity	Premix or engineered active-excipient granules
Faster disintegration	Controlled sodium starch glycolate or crospovidone
Reduced sticking	Low-level magnesium stearate with process optimization
Lactose-free positioning	Mannitol, dicalcium phosphate or alternative cellulose systems
Improved patient acceptability	Smaller tablet, film-coating optimization and differentiated color coding

Any substitution must be evaluated against dissolution, assay, content uniformity, impurity profile, stability and bioequivalence requirements. An excipient change that improves manufacturability but alters absorption can create a regulatory problem.

What formulation patents protect Avandia?

The principal intellectual-property barriers associated with Avandia were directed primarily to rosiglitazone and its therapeutic use rather than to a technically complex excipient platform. The product is a small-molecule immediate-release tablet, and the branded formulation does not depend on a highly differentiated delivery system.

Key patent categories historically relevant to rosiglitazone included:

1. Composition-of-matter protection for rosiglitazone or related thiazolidinedione compounds.
2. Pharmaceutical compositions containing rosiglitazone.
3. Methods of treating type 2 diabetes.
4. Combination therapy involving rosiglitazone and other glucose-lowering agents.
5. Specific salts, dosage forms or manufacturing processes.

The original product patents and FDA regulatory exclusivities have expired. The commercial position is therefore different from a product protected by a current extended-release, device or biologic formulation patent. Current developers must verify live claims in the relevant jurisdiction because patent status can vary by family member, terminal disclaimer, pediatric extension and litigation outcome.

When does Avandia lose exclusivity?

Avandia lost meaningful U.S. market exclusivity years ago. The FDA approved Avandia in 1999, and the five-year new chemical entity exclusivity period expired well before the present market period. The principal patent estate also no longer prevents generic rosiglitazone marketing in the United States.

The product’s commercial erosion was accelerated by safety-related regulatory action. In 2010, FDA required stronger cardiovascular risk controls, and in 2011 it imposed a restricted distribution program. FDA later removed the special dispensing restrictions in 2017 after reviewing new evidence, while retaining labeling warnings concerning cardiovascular risk (FDA, 2017).

Milestone	Approximate timing
FDA approval of Avandia	1999
NCE exclusivity expiration	2004
Core patent barriers	Expired or commercially ineffective by the 2010s
Restricted distribution controls	2010-2011
FDA removal of special access restrictions	2017
Current commercial position	Mature generic small molecule

The absence of current regulatory exclusivity does not eliminate the need to assess patent listings, pending litigation or jurisdiction-specific rights before launch. It does mean that a conventional ANDA pathway is the central U.S. regulatory route.

What is the Orange Book status of Avandia?

Avandia is an FDA-approved small-molecule drug listed in the Orange Book framework. The relevant regulatory pathway for a generic rosiglitazone tablet is generally an abbreviated new drug application demonstrating pharmaceutical equivalence and bioequivalence to the reference-listed drug.

Important Orange Book considerations include:

• The reference product designation for rosiglitazone tablets.
• Product-specific dosage strengths.
• Any listed patents and their expiration status.
• The availability of approved ANDA products.
• Whether the brand is currently marketed or discontinued.
• Any therapeutic-equivalence rating for approved generic products.

A discontinued brand can remain relevant as a reference product even when the sponsor no longer actively markets it. FDA’s Orange Book and Drugs@FDA records should be used together because marketing status, approval status and patent information serve different regulatory purposes (FDA, n.d.-a; FDA, n.d.-b).

Are Paragraph IV challenges relevant to Avandia?

Paragraph IV litigation was commercially relevant during the period when rosiglitazone patents remained enforceable. Generic applicants could challenge listed patents by asserting that the patents were invalid, unenforceable or not infringed.

The practical significance of Paragraph IV risk is now lower because the principal barriers have expired. A new applicant would more likely rely on:

• A Paragraph III certification if a listed patent remains valid but expires before launch.
• A Paragraph IV certification if a live patent is listed.
• A section viii statement for patents directed only to an unclaimed method of use.
• A standard ANDA strategy where no blocking patent remains.

The risk profile is therefore mainly administrative and jurisdiction-specific rather than a major barrier to U.S. entry.

What method-of-use patents affect rosiglitazone?

Rosiglitazone method-of-use claims historically covered treatment of insulin resistance, type 2 diabetes and use with other antidiabetic agents. Combination products included rosiglitazone with metformin and glimepiride.

Method-of-use patents can affect generic labeling when the reference product has multiple indications. An ANDA applicant may seek a label that omits a patented indication through a section viii carve-out. This approach requires careful control of promotional materials, prescribing information and distribution channels.

For rosiglitazone, method-of-use protection is no longer the principal commercial constraint. The more material issue is whether a new product can generate demand despite the availability of lower-cost alternatives and the drug’s cardiovascular safety history.

What commercial opportunities exist for rosiglitazone excipients?

1. Low-cost generic tablets

The strongest opportunity is a reliable, low-cost immediate-release tablet. A manufacturer with efficient compression, testing and packaging can compete through unit cost, supply continuity and multi-strength availability.

Because the product is mature, formulation novelty is less valuable than:

• High batch yield.
• Low tablet rejection.
• Stable dissolution across sites.
• Consistent low-dose uniformity.
• Efficient packaging.
• Limited dependence on a single excipient supplier.

2. Lactose-free formulations

A lactose-free tablet could target patients with excipient sensitivities, institutional buyers with standardized formulary policies or export markets with different excipient preferences. This is a positioning opportunity, not a major clinical differentiator.

Possible alternatives include mannitol, anhydrous dibasic calcium phosphate and selected grades of microcrystalline cellulose. Each alternative changes tablet density, compressibility, disintegration and dissolution. The product would require full comparative development rather than a simple excipient substitution.

3. Smaller or easier-to-swallow tablets

Rosiglitazone dose strengths are low, so tablet size can be reduced through higher-density excipients or more efficient compression. A smaller tablet could support adherence and improve acceptability among patients taking several chronic medicines.

The commercial effect is likely modest unless paired with a branded generic strategy, a combination product or a specific institutional contract.

4. Fixed-dose combinations

Fixed-dose products involving rosiglitazone and metformin or glimepiride have a stronger commercial rationale than a single-agent reformulation. Combination products can reduce pill burden and improve regimen simplicity.

The barriers include:

• Separate dose titration requirements.
• Different dissolution and stability requirements.
• Potentially incompatible compression behavior.
• More complex clinical and labeling considerations.
• Limited demand because clinicians may prefer newer agents with better cardiovascular or weight profiles.

5. Emerging-market supply

Rosiglitazone may remain commercially relevant in price-sensitive markets where newer GLP-1 receptor agonists, SGLT2 inhibitors and insulin products are less accessible. The opportunity depends on local approval, reimbursement, prescriber practice and national safety restrictions.

A region-specific excipient strategy may be useful where local supply chains favor starches, mannitol or calcium phosphate over imported specialty cellulose grades. Packaging stability under high heat and humidity is also important for tropical markets.

How strong is the Avandia patent estate?

The current patent estate is weak as a commercial barrier for conventional rosiglitazone tablets. The drug has:

• An expired core composition-of-matter position.
• Expired or commercially exhausted regulatory exclusivity.
• No essential biologic manufacturing platform.
• No complex delivery device.
• No meaningful biosimilar barrier.
• A conventional tablet process that generic manufacturers can reproduce.

Potential residual protection may exist around particular combinations, formulations or jurisdictions, but those rights do not recreate the former branded exclusivity position. The commercial moat is therefore operational rather than patent-based.

What generic entry risks exist for Avandia?

Generic launch risk is driven by market economics and regulatory perception rather than formulation complexity.

Risk	Commercial impact
Low demand after safety restrictions	Limits return on formulation investment
Competition from newer diabetes drugs	Reduces prescriber interest
Low generic price	Compresses gross margin
Low-dose content-uniformity failure	Can delay approval or trigger batch failures
Supply interruption	Can create short-term market share gains
Safety-related prescribing caution	Limits patient volume
Multiple approved suppliers	Increases price competition
Combination-product competition	Reduces value of single-agent tablets

A contract manufacturer can produce the product efficiently, but a new entrant would need a credible channel strategy. Hospital, government and international tenders may offer more realistic volume than U.S. retail branding.

How does Avandia compare with newer diabetes products?

Attribute	Rosiglitazone	Metformin	SGLT2 inhibitors	GLP-1 receptor agonists
Dosage form	Immediate-release tablet	Tablet	Tablet	Mostly injectable, some oral
Excipient complexity	Low	Low to moderate	Moderate	Higher, especially injectables
Patent position	Mature and largely expired	Mature and expired	Product-specific estates remain important	Strong product and formulation estates
Manufacturing barrier	Low	Low	Moderate	High for biologics and peptides
Weight effect	Weight gain risk	Usually weight neutral	Weight reduction	Weight reduction
Cardiovascular positioning	Safety concern limits use	Established first-line role	Outcome-driven demand	Outcome-driven demand
Generic opportunity	Price-driven	Large mature market	Emerging by product	Limited biosimilar or follow-on opportunity

Rosiglitazone is easier to manufacture than most newer diabetes products, but that technical simplicity is matched by weaker demand and lower pricing power.

Does Avandia have biosimilar risk?

No. Avandia is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is the ANDA generic pathway, not the biosimilar pathway under the Public Health Service Act.

This distinction reduces development cost and regulatory complexity. It also means that once patent and exclusivity barriers expire, multiple manufacturers can compete directly on the same active ingredient and dosage form.

What licensing deals and litigation affect commercial entry?

Historical rosiglitazone commercialization involved GlaxoSmithKline as the principal branded sponsor. Generic entry and patent disputes were associated with ANDA filings and challenges to rosiglitazone-related patents. Those disputes were commercially important while patent rights remained active.

Current licensing value is limited for a standard rosiglitazone tablet because the active ingredient and basic formulation are not controlled by a high-value platform patent. A licensing transaction could still have value for:

• Regional marketing rights.
• Government tenders.
• Fixed-dose combinations.
• Manufacturing capacity.
• Local regulatory dossiers.
• Supply agreements for a validated API or finished product.

Any transaction should be assessed against current FDA approval status, Orange Book records, local patent registers, product liability exposure and post-market safety obligations.

Key Takeaways

• Avandia is a conventional immediate-release rosiglitazone maleate tablet with a low-complexity excipient platform.
• The core formulation uses common excipients, including lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate and film-coating materials.
• The best generic strategy is to optimize low-dose content uniformity, dissolution, compression and supply reliability.
• The principal patent and regulatory exclusivity barriers have expired or lost practical commercial effect.
• Avandia has no biosimilar barrier because rosiglitazone is a small molecule.
• Commercial opportunities are strongest in low-cost generics, emerging markets, institutional supply and selected fixed-dose combinations.
• New branded reformulation opportunities are limited by safety perception, competition from newer diabetes therapies and low pricing power.
• Excipient innovation can improve manufacturability and patient usability, but it is unlikely by itself to create meaningful market exclusivity.

FAQs

Is Avandia still approved by the FDA?

Yes. FDA approval remains distinct from active brand marketing. The FDA removed special dispensing restrictions in 2017, but rosiglitazone labeling continues to contain cardiovascular safety information.

What is the best excipient for a generic rosiglitazone tablet?

No single excipient is universally optimal. A lactose-microcrystalline-cellulose system with a controlled superdisintegrant is a practical starting point, subject to blend uniformity, dissolution and stability testing.

Can rosiglitazone be formulated as an extended-release tablet?

Technically, extended-release development is possible, but the commercial case is weak unless the product demonstrates a meaningful adherence, tolerability or pharmacokinetic advantage. A new dosage form would also require additional clinical and regulatory work.

Is a lactose-free Avandia generic commercially differentiated?

It can provide a niche differentiation point, especially in selected markets or institutional channels. It is unlikely to support premium pricing without a broader patient or clinical advantage.

What is the main barrier to launching a new rosiglitazone product?

The main barrier is commercial demand, not formulation technology. Low-cost generics, cardiovascular safety concerns and competition from newer diabetes medicines constrain expected returns.

References

1. U.S. Food and Drug Administration. (2010). Avandia (rosiglitazone maleate) tablets prescribing information. FDA.

2. U.S. Food and Drug Administration. (2017). FDA approves new label changes for rosiglitazone-containing diabetes medicines. FDA Drug Safety Communication.

3. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. FDA.

5. National Library of Medicine. (n.d.). DailyMed: Avandia-rosiglitazone maleate tablet, film coated. U.S. National Library of Medicine.